Daniel Pella, Rastislav Šidlo
Clinical programme PULSE 2011 (Klinický Program zameraný na zlepšenie kvality života U pacientov Liečených pre Stabilnú angínu pEktoris) was focused on quality of life improvement (evaluated by number of angina pectoris attacks per week and number of sublingual forms of nitroglycerin used) in patients with stable angina pectoris. Treatment of choice was heart rate reduction by fortified treatment. We have evaluated patients with documented coronary artery disease with syndrome of stable angina pectoris despite previous pharmacological treatment, including betablockers (as far as they were contraindicated or not tolerated due to adverse effects). Heart rate over 70 beats /min. was a key inclusion criterion. There were 1733 patients included into the programme. Ivabradine (Procoralan®) in the dose 2x5 mg daily was added to the treatment with optional up or down-titration during the programme course. After 3 months of therapy we observed not only statistically significant decrease of heart rate from 84.42 ± 9.77 beats/min. to 64.85 ± 6.10 beats/min. (p<0.0001), but above all, statistically significant decrease of angina pectoris attacks from 3.72 ± 3.11 to 0.86 ± 1.06 per week (p<0.0001) and significant reduction of sublingual nitroglycerin administrations from 3.19 ± 3.04 to 0.62 ± 1.07 per week were observed (p<0.0001). Quality of life of the patients (evaluated by simple questionnaire) significantly improved at the end of the programme in comparison with baseline visit (p<0.0001). Moreover, we found significant decrease of pain threshold and its intensity classified by CCS (Canadian Cardiovascular Society). We have confirmed that ivabradine (Procoralan®) improved quality of life in patients with stable angina pectoris by significant reduction of frequency and intensity of angina pectoris attacks.